Literature DB >> 26187019

HIV-2EU-Supporting Standardized HIV-2 Drug-Resistance Interpretation in Europe: An Update.

Charlotte Charpentier1, Ricardo Camacho2, Jean Ruelle3, Josef Eberle4, Lutz Gürtler4, Alejandro Pironti5, Martin Stürmer6, Françoise Brun-Vézinet7, Rolf Kaiser8, Diane Descamps1, Martin Obermeier9.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 26187019     DOI： 10.1093/cid/civ572

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  7 in total

Review 1.  Approved Antiviral Drugs over the Past 50 Years.

Authors:  Erik De Clercq; Guangdi Li
Journal:  Clin Microbiol Rev       Date:  2016-07       Impact factor: 26.132

2.  A Trial of a Single-tablet Regimen of Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Disoproxil Fumarate for the Initial Treatment of Human Immunodeficiency Virus Type 2 Infection in a Resource-limited Setting: 48-Week Results From Senegal, West Africa.

Authors:  Selly Ba; Dana N Raugi; Robert A Smith; Fatima Sall; Khadim Faye; Stephen E Hawes; Papa Salif Sow; Moussa Seydi; Geoffrey S Gottlieb
Journal:  Clin Infect Dis       Date:  2018-10-30       Impact factor: 9.079

3.  MK-8591 (4'-Ethynyl-2-Fluoro-2'-Deoxyadenosine) Exhibits Potent Activity against HIV-2 Isolates and Drug-Resistant HIV-2 Mutants in Culture.

Authors:  Vincent H Wu; Robert A Smith; Sara Masoum; Dana N Raugi; Selly Ba; Moussa Seydi; Jay A Grobler; Geoffrey S Gottlieb
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

4.  HIV-2 Primary Infection in a French 69-Year-Old Bisexual Man.

Authors:  Nicolas Cazals; Quentin Le Hingrat; Bruno Abraham; Patricia Da Silva; Laure Guindre; Sylvie Goffart; Florence Damond; Benoît Visseaux; Charlotte Charpentier; Sylvie Ranger-Rogez; Diane Descamps
Journal:  Open Forum Infect Dis       Date:  2018-09-11       Impact factor: 3.835

5.  First-line Raltegravir/Emtricitabine/Tenofovir Combination in Human Immunodeficiency Virus Type 2 (HIV-2) Infection: A Phase 2, Noncomparative Trial (ANRS 159 HIV-2).

Authors:  Sophie Matheron; Diane Descamps; Sebastien Gallien; Amel Besseghir; Pierre Sellier; Laurent Blum; Emmanuel Mortier; Charlotte Charpentier; Roland Tubiana; Florence Damond; Gilles Peytavin; Diane Ponscarme; Fideline Collin; Francoise Brun-Vezinet; Genevieve Chene
Journal:  Clin Infect Dis       Date:  2018-09-28       Impact factor: 9.079

6.  Exploration of the effect of sequence variations located inside the binding pocket of HIV-1 and HIV-2 proteases.

Authors:  Dhoha Triki; Telli Billot; Benoit Visseaux; Diane Descamps; Delphine Flatters; Anne-Claude Camproux; Leslie Regad
Journal:  Sci Rep       Date:  2018-04-10       Impact factor: 4.379

Review 7.  HIV treatment in Guinea-Bissau: room for improvement and time for new treatment options.

Authors:  S Jespersen; F Månsson; J Lindman; C Wejse; C Medina; Z J da Silva; DdS Te; P Medstrand; J Esbjörnsson; B L Hønge
Journal:  AIDS Res Ther       Date:  2020-02-04       Impact factor: 2.250
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.